Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Gains from Sales and Divestitures (2019 - 2023)

Bicycle Therapeutics (BCYC) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $119144.0 as the latest value for Q4 2023.

  • For Q4 2023, Gains from Sales and Divestitures rose 240.41% year-over-year to $119144.0; the TTM value through Dec 2023 reached $119144.0, up 240.41%, while the annual FY2023 figure was $119144.0, 240.41% up from the prior year.
  • Gains from Sales and Divestitures hit $119144.0 in Q4 2023 for Bicycle Therapeutics, up from $99638.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $119144.0 in Q4 2023 and bottomed at $35000.0 in Q1 2022.
  • Average Gains from Sales and Divestitures over 3 years is $67853.8, with a median of $78781.0 recorded in 2023.
  • On a YoY basis, Gains from Sales and Divestitures climbed as much as 240.41% in 2023 and fell as far as 62.82% in 2023.
  • Bicycle Therapeutics' Gains from Sales and Divestitures stood at $83947.0 in 2019, then plummeted by 58.31% to $35000.0 in 2022, then soared by 240.41% to $119144.0 in 2023.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $119144.0, $99638.0, and $78781.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.